Managed Medical Review Organization, Inc. (MMRO) announced on September 4, 2026 that it has earned URAC’s Artificial Intelligence in Health Care Accreditation, Version 1.0, according to a company release distributed through PRNewswire. The Washington-based independent review organization, which has held URAC’s separate Independent Review Organization accreditation for more than 15 years, is among the first cohort of health care companies to complete the AI-specific certification since URAC opened the program in 2025.
What URAC’s AI accreditation actually checks
URAC, a nonprofit accrediting body long used by health plans and utilization review firms to certify clinical and operational standards, built the AI program around two tracks: one for companies that develop AI tools and one for organizations that deploy AI built by others. According to URAC’s own announcement of the program’s 2025 launch, the standards were shaped by a 29-member national Health Care AI Advisory Committee and cover governance, transparency, bias testing, data security and ongoing performance monitoring rather than certifying any single algorithm’s clinical accuracy.
What MMRO says it did to qualify
MMRO’s release states the company spent roughly a year building a formal AI governance program that includes responsible-use policies, documented risk and impact assessments, and testing and training requirements mapped to URAC’s framework. The company credits its Vice President of Clinical Programs, Jen Mongeau, DHA, MBA, MSN, RN, with leading clinical oversight of how AI tools are used inside MMRO’s independent medical review work, which includes evaluating insurer decisions on medical necessity — precisely the kind of determination that has drawn scrutiny elsewhere in the industry.
Why this lands differently than a typical accreditation press release
Utilization review and independent review organizations sit at a sensitive point in the health system: they are often the entity insurers or state regulators call on to adjudicate disputed medical necessity decisions, sometimes the same category of decision that has triggered class-action lawsuits against large insurers over AI-driven claim denials in states including California and Minnesota. An accreditation specifically targeting how AI is governed inside review organizations, rather than inside insurers themselves, is a narrower but arguably more targeted response to that controversy — it certifies the reviewer’s own AI use, not the AI tool an insurer used to generate the original denial.
The skeptical read on voluntary accreditation
URAC accreditation is voluntary and industry-funded, and critics of self-regulatory frameworks note that accreditation bodies have financial incentives to expand membership rather than impose standards so strict that companies decline to apply. Unlike FDA clearance for a diagnostic algorithm, URAC’s AI accreditation does not certify clinical accuracy or effectiveness of any specific model; it certifies governance process. Patient advocates who have criticized AI-driven claim denials argue that process accreditation, however rigorous, does not by itself guarantee that a specific AI-assisted review reached the medically correct outcome in an individual patient’s case.
Where this sits in a fast-forming regulatory patchwork
States have moved faster than federal regulators on AI in insurance and utilization review: Colorado’s Consumer Protections in Interactions with Artificial Intelligence Systems Act, which directly addresses AI in utilization management and requires bias testing, disclosure and appeal rights, had its implementation pushed to June 2026 after a special legislative session, according to legal trade coverage. Voluntary accreditation programs like URAC’s are emerging in that gap, offering companies a way to signal responsible AI governance ahead of, or instead of, binding state law — a pattern seen previously with URAC’s telehealth and health plan accreditations.
What’s next
URAC has said it expects uptake of the AI accreditation to keep growing through 2026 as more health plans, utilization review firms and AI vendors seek the certification amid rising legal and legislative pressure over automated coverage decisions. The next test will be whether accreditation correlates with fewer denied-claim lawsuits or regulatory complaints against accredited firms compared with unaccredited peers — data URAC has not yet published. Watch for additional utilization review organizations to announce accreditation in the coming months, and for state insurance regulators to weigh whether to reference URAC’s standard directly in future AI oversight rules. Patient advocacy groups that have pushed for stronger AI disclosure requirements in utilization review say they will be watching whether accredited firms like MMRO voluntarily publish plain-language summaries of how AI is used in specific coverage determinations, rather than limiting transparency to the accreditation process itself.
